“Adalimumab for Nail Psoriasis: Efficacy and Safety from the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial” (2017) SKIN The Journal of Cutaneous Medicine, 1(3.1), p. s97. doi:10.25251/skin.1.supp.96.